News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FivePrime Therapeutics, Inc. Announces That Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand Trap


6/4/2012 10:02:38 AM

SOUTH SAN FRANCISCO, Calif., June 4, 2012 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (FivePrime), a leader in the discovery and development of innovative biologics, announced today that Human Genome Sciences (HGS) has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to initiate a Phase 1b human clinical trial of HGS1036/FP-1039 in combination with multiple anti-cancer regimens.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES